October 11, 2023
Araclon Biotech to highlight clinical data on its Alzheimer’s vaccine at upcoming scientific conferences
- Presentations on clinical progress of Araclon’s ABvac40 program include final phase 2 study results in late-breaking presentation at CTAD 2023
- Araclon’s previously reported ABvac40 interim phase 2 findings demonstrated promising safety, tolerability and a robust immune response in Alzheimer’s patients
Zaragoza, Spain, October 11, 2023 – Araclon Biotech, a Grifols Group company dedicated to the research and development of therapies and diagnostic methods applied to neurodegenerative diseases, today announced participation at upcoming scientific conferences to present clinical data from studies of its Alzheimer’s vaccine candidate, ABvac40 (NCT03461276), for treatment of patients with Alzheimer’s disease (AD).
This will include a late-breaking presentation of previously unreleased final results from Araclon’s phase 2 study of ABvac40 at the Clinical Trials on Alzheimer’s Disease 2023 (CTAD) conference, in addition to discussions of the ABvac40 program at the 2023 European Alzheimer’s Disease Consortium (EADC) and the Annual Meeting of the Spanish Society of Neurology 2023 (SEN).
ABvac40 is a clinical vaccine developed to specifically target the Αβ40 peptide, a key pathological feature associated with AD. In addition, deposition of Αβ40 in the brain plays a primary role in cerebral amyloid angiopathy, a highly prevalent condition among AD patients.
Based on its phase 2 interim findings presented at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PDTM 2022), ABvac40 demonstrated promising safety, tolerability and a robust immune response in patients with amnestic mild cognitive impairment (aMCI) or very mild AD (vm-AD). These results were confirmed with the complete interim readout of the study presented at the 2023 Alzheimer’s Association International Conference (AAIC 2023).
Upcoming presentation details can be found below.
Presentation Details:
Event: European Alzheimer’s Disease Consortium Meeting 2023
Location: Aula Benvenuto, 5th Floor, University of Genoa, Genova, Italy
Date & Time: October 12, 2023, 4:15pm CET
Presentation Title: ABvac40: A novel Alzheimer vaccine against Aβ40 peptide
Event: Clinical Trials on Alzheimer’s Disease 2023 Conference
Location: Grand Ballroom AB – Floor 2 Mezzanine Level, Boston Park Plaza, Boston, Massachusetts
Date & Time: October 24, 2023, 6:20pm ET
Late-breaking Presentation Title: Safety, immunogenicity, clinical efficacy and biomarkers of ABvac40, an active vaccine anti-Aβ40 in patients with amnestic mild cognitive impairment of very mild Alzheimer’s disease: final results of a phase 2 randomized study
Event: 75th Annual Meeting of the Spanish Society of Neurology
Location: Recatí A Room, Hotel Sercotel Sorolla, Valencia, Spain
Date & Time: November 1, 2023, 1:30pm – 3:30pm CET
Seminar Title: Araclon Biotech: Advances in early diagnosis and treatment of Alzheimer’s disease
About Araclon Biotech
Araclon Biotech specializes in researching and developing therapies and diagnostic methods for Alzheimer's disease (AD) and other neurodegenerative diseases. The company, in which Grifols holds a stake of almost 76%, focuses on two research areas: the early diagnosis of AD by means of detecting amyloid-beta peptides in the blood, and the treatment of the disease using immunotherapy (vaccines).